Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06785337

"The Effect of Inhaled Nitroglycerin for COPD Patients

this study aims to investigative the benefits of using nebulized nitroglycerin in improving respiratory functions in patients of late stage COPD

Recruiting

Interested in participating?

Request Info

Key information

Conditions

COPD COPD III/IV Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Aspiration Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Haram Hospital

Haram, Giza Governorate, 12556, Egypt

Location status: Recruiting

Location contact

Asia said Toukhy, assistant lecturer

PRINCIPAL_INVESTIGATOR

asia said Toukhy, head of clinical pharmacy

CONTACT

[email protected]

01127424017

About this study

the inhaled nitroglycerin is expected to make vasodilatation of the pulmonary arteries and arterioles which are constricted in late stages of COBD leading to ventilation/perfusion mismatching and further aggravating COPD. it will also help in delivering better antibiotic concentrations to the alveoli which help in better control of infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient's ≥ 18 years old COPD exacerbation with respiratory failure and Echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure > 20 mmHg)

Exclusion criteria

  • Profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. This may worsen cardiogenic pulmonary edema.
  • Pregnant female patients
  • Patient with hypersensitivity to nitroglycerin

Treatment and study plan

Inhaled nitroglycerin

Drug

Inhaled nitroglycerin

Primary outcomes

  1. Change in pulmonary functions

    Time frame: 5 days after start of nebulized nitroglycerin

    Change in pulmonary functions Defined as:

    • Reduction of PaCO2 in arterial blood gases from admission value.
    • increase in Pao2 from admission value.

Secondary outcomes

  1. Number of days on mechanical ventilation

    Time frame: 5 days after start of nebulized nitroglycerin

  2. Dose of vasopressor therapy

    Time frame: 5 days after start of nebulized nitroglycerin

  3. Reduction of WBC count

    Time frame: 10 days after start of nebulized nitroglycerin

  4. Mortality rate

    Time frame: 10 days after start of nebulized nitroglycerin

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"

Acronym: iNGCOPD

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 21, 2025
Registry last updated
Jan 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.